Skip to content

Multi-Site, Post-Market Study of the ICONACY I-Hip System

Non-Randomized, Multi-Site, Post-Market Study of the ICONACY I-Hip System (Protocol No. PS-1001)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02131389
Enrollment
500
Registered
2014-05-06
Start date
2014-04-30
Completion date
2019-12-31
Last updated
2014-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Joint Disease

Keywords

Hip, Arthroplasty, Arthroplasties, Prosthesis, Iconacy, Osteoarthritis, Arthritis, THA, THR, DJD

Brief summary

The purpose of this study is to evaluate the use and efficacy of the I-Hip for primary total hip replacement surgery.

Interventions

Sponsors

Iconacy Orthopedic Implants, LLC.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* A candidate for primary hip replacement on this operative hip. * Is 30 to 80 years of age. * Has hip joint disease related to one or more of the following: * Degenerative joint disease, (including osteoarthritis or post-traumatic arthritis) * Avascular Necrosis (AVN). * Will be available for evaluation for the duration of the study. * Is able and willing to speak and read English, read and sign the informed consent, fill out the WOMAC and Patient Satisfaction questionnaires, and follow all study procedures.

Exclusion criteria

* Is younger than 30 years of age or older than 80 years of age. * Has undergone partial hip replacement or previous ORIF (open reduction internal fixation of femur or acetabulum). * Has undergone total hip replacement on this hip in the past (no revisions allowed in study). * Infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection. * Is currently experiencing radicular pain from the spine down operative leg. * Has participated in an IDE/IND clinical investigation with an investigational product in the last three months, or is involved in any personal injury litigation, medical-legal or worker's compensation claim. * Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires. * Has been diagnosed with fibromyalgia or has a significant neurological or musculoskeletal disorder or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, Charcot disease). * Has been diagnosed with Paget's disease or Congenital hip deformity (dysplasia and/or dislocation). * Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.) * Is Obese: (Defined for this study as having a BMI\>45). * Has insufficient bone quality. * Has loss of ligamentous structures. * Has materials sensitivity. * Is currently a prisoner. * Is pregnant or lactating. * Has a contralateral amputation. * Has a medical condition with less than 2 years of life expectancy.

Design outcomes

Primary

MeasureTime frameDescription
Radiographic Success as a Measure of Radiolucency and Component Migration2 yearsA subject will be considered a failure for Overall Radiographic Success if one or more of the below conditions are met: The subject will be considered a RADIOGRAPHIC FAILURE if: 1. there is a complete radiolucent line\> 3mm wide at the bone/cement interface or 2. there is a \>5 degree migration (shift) of the component or 3. there is a \>5 mm migration (shift) of the component.
Improvement of Harris Hip Score (with Charnley Score and other comorbidities considered)2 years
Patient satisfaction clinical assessment utilizing questionnaire2 yearsClinical assessment of patient satisfaction will be made by utilizing a Patient Satisfaction (PS) questionnaire.

Secondary

MeasureTime frame
Revision of Implant Prosthesis as a Measure of Efficacy5 years

Countries

United States

Contacts

Primary ContactDonald L Pomeroy, MD
arthroplastyfoundation@gmail.com502-364-9883
Backup ContactJan Empson, RN
empsonja@aol.com502-364-0902

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026